Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov;127(11):1585-1589.
doi: 10.1016/j.ophtha.2020.05.003. Epub 2020 May 8.

Immune Checkpoint Inhibitor-Associated Optic Neuritis

Jasmine H Francis  1 , Korey Jaben  2 , Bianca D Santomasso  3 , Julia Canestraro  4 , David H Abramson  2 , Paul B Chapman  5 , Meghan Berkenstock  6 , Mary E Aronow  7
Affiliations

Immune Checkpoint Inhibitor-Associated Optic Neuritis

Jasmine H Francis et al. Ophthalmology. 2020 Nov.

Abstract

The three classes of immune checkpoint inhibitors can be associated with optic neuritis, which typically presents with bilateral, painless visual decline. Visual function stabilized with drug cessation and systemic steroids.

PubMed Disclaimer

Comment in

References

    1. Dalvin LA, Shields CL, Orloff M, et al.CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects. Retina (Philadelphia, Pa) 2018;38:1063–1078. - PubMed
    1. Kim JM, Materin MA, Sznol M, et al.Ophthalmic Immune-Related Adverse Events of Immunotherapy: A Single-Site Case Series. Ophthalmology 2019;126:1058–1062. - PMC - PubMed
    1. Yeh OL, Francis CE. Ipilimumab-associated bilateral optic neuropathy. J Neuroophthalmol 2015;35:144–147. - PubMed
    1. Wilson MA, Guld K, Galetta S, et al.Acute visual loss after ipilimumab treatment for metastatic melanoma. J Immunother Cancer 2016;4:66. - PMC - PubMed
    1. Mori S, Kurimoto T, Ueda K, et al.Optic Neuritis Possibly Induced by Anti-PD-L1 Antibody Treatment in a Patient with Non-Small Cell Lung Carcinoma. Case Rep Ophthalmol 2018;9:348–356. - PMC - PubMed

Publication types

Substances